ArticleScientific reports2021
Dynamics of detailed components of metabolic syndrome associated with the risk of cardiovascular disease and death.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Multistate markov model analysis of metabolic syndrome progression in a community-based longitudinal cohort study.Diabetology & metabolic syndrome · 2026Article
- Physical Activity and Bidirectional Stage Transitions in Cardiovascular-Kidney-Metabolic Syndrome: A Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Prevalence of the Metabolic Syndrome and its Associated Factors among Hospital Workers at a Rwandan Provincial Hospital: A Cross-Sectional Study.Rwanda journal of medicine and health sciences · 2025Article
- The effects of time-restricted feeding on early vascular, liver, and renal structural changes, oxidative stress, and inflammation in obese rats.Scientific reports · 2025Article
- Association of metabolic syndrome components and their combinations with functional disability among older adults in a longevity-associated ethnic minority region of Southwest China.Frontiers in public health · 2025Article
- Metabolic syndrome clustering patterns and the association with cardiovascular disease among post-menopausal Korean women.Scientific reports · 2024Article
- Causal association study of the dynamic development of the metabolic syndrome based on longitudinal data.Scientific reports · 2024Article
- The Metabolic Syndrome, a Human Disease.International journal of molecular sciences · 2024Review
- Research on the relationship between common metabolic syndrome and meteorological factors in Wuhu, a subtropical humid city of China.BMC public health · 2023Article
- Cost-Effectiveness Analysis of Personalized Hypertension Prevention.Journal of personalized medicine · 2023Article
- Study on Dynamic Progression and Risk Assessment of Metabolic Syndrome Based on Multi-State Markov Model.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Modulation of the Gut Microbiota by Fufang-Zhenzhu-Tiaozhi Capsule Attenuates Hypertension Induced by a High-Fructose and High-Salt Diet.Frontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few studies quantify a cascade of dynamic transitions on the detailed components of metabolic syndrome (MetS) and subsequent progressions to cardiovascular disease (CVD) and its death. A total of 47,495 subjects repeatedly attending a community-based integrated screening program in Taiwan were recruited. The refined MetS-related classification (RMRC) in relation to five criteria of MetS was defined as free of metabolic disorder (FMD, none of any criteria), mild metabolic disorder (MMD, 1-2 criteria) and MetS. A multistate Markov model was used for modelling such a multistate process. The estimated progression rate from FMD to MMD was 44.82% (95% CI 42.95-46.70%) whereas the regression rate was estimated as 29.11% (95% CI 27.77-30.45%). The progression rate from MMD to MetS was estimated as 6.15% (95% CI 5.89-6.42%). The estimated annual incidence rates of CVD increased with the severity of RMRC, being 1.62% (95% CI 1.46-1.79%) for FMD, 4.74% (95% CI 4.52-4.96%) for MMD, to 20.22% (95% CI 19.52-20.92%) for MetS. The estimated hazard rate of CVD death was 6.1 (95% CI 4.6-7.7) per thousand. Elucidating the dynamics of MetS-related transition and quantifying the incidence and prognosis of CVD provide a new insight into the design and the evaluation of intervention programs for CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.